Page 2 - Natco Pharma

Natco Pharma reports 14.5% decline in net profit at Rs 122 cr for Q1

The company had posted a net profit of Rs 142.8 crore for the corresponding period of the previous fiscal

Stock picks by Sameet Chavan of Angel Broking: Buy Natco Pharma, IRB Infra

The entire pharma space has been in limelight since the coronavirus pandemic outbreak

Natco Pharma Q4 PBT down 23% at Rs 117 cr on decline in Hep C portfolio

Total income for the quarter down marginally to Rs 477.2 cr; full-year pre-tax at Rs 569 cr

Taiho Pharma moves US court against Natco for patent infringement

Taiho alleged that the Indian drug maker's proposed generic Lonsurf (trifluridine and tipiracil) will infringe the patent

Huge relief for cardio-diabetic patients as three key drugs go off patent

The prices have already dropped by almost 80% in most cases.

Natco Pharma profit before tax drops 40% in Q2 to Rs 139 cr on tepid sales

The board of directors of Natco Pharma has recommended second interim dividend of Rs 1 per equity share of Rs 2 each

Natco in legal fight with FMC to produce CTPR based insecticide in India

Natco is also awaiting regulatory approval for a product based on CTPR, which is a broad spectrum insecticide used in several crops

Natco Pharma's API facility near Hyderabad gets 6 USFDA observations

The company said that key points of the observations in Form 483 are the supplier and service provider agreements to be made more robust

USFDA completes Chennai facility audit with zero observations: Natco Pharma

Shares of Natco Pharma were trading 0.35 per cent higher at Rs 529.95 apiece on BSE

Natco Pharma gets 9 observations from US drugs regulator for Kothur plant

The Food and Drug Administration's observations were procedural and "can be addressed within a short period of time", says Natco.

Natco Pharma Q4 net profit down 60% at Rs 120 crore; FY19 income dips

Natco Pharma revenues decreased by 38 per cent to Rs 486.7 crore in Q4, compared to Rs 787.9 crore in the year-ago period

Lack of new launches in near term a worry for Natco Pharma stock

Lack of significant launch visibility has led analysts to estimate net profit numbers to be little changed next year

Natco Pharma Q3 net down 26% to Rs 159 cr on flat revenue, fall in margins

Margin reduction of Oseltamivir in the US market cited as the major cause for the decline in profits during the quarter

Natco Pharma to enter agrochemicals, set up Rs 100 crore facility in AP

The decision marks Natco's first ever entry into agrochemical manufacturing, an all together a new area of business for a pharma player

Natco Pharma shifts focus from US, to spend 70% funds in emerging markets

60-70% of the R&D spend will be for developing portfolio in Brazil, Canada, China & India

Natco Pharma to commence Rs 2.5-billion share buyback on November 19

The company has proposed to buy a minimum number of 1.25 million shares from the open market route in the six-month period

Natco Pharma looks to improve domestic revenues with more product launches

Domestic market has contributed a third of Natco Pharma's revenues of Rs 22 billion in 2017-18, though slipped in sales for the first time

Fresh triggers kick in for Natco, market share gains for copaxone drug

Natco Pharma remains as one of the few Indian pharma companies to have medium-term revenue visibility

Natco Pharma bets on complex generics to build its international biz

The company has a strong oncology product portfolio, forming a significant portion of its domestic business

Natco: Stock correction an opportunity as earnings trajectory remains firm

Natco Pharma, which was one of the few outperformers in the pharma pack until recently, has seen its share price fall by a fourth since its January highs of Rs 1,050 levels. While the launch of its mega blockbuster product, Copaxone generics (oncology treatment) in the US was among key reasons for earlier gains, some disappointment in the December quarter results (Q3) coupled with weakness in broader markets has contributed to the recent correction. Nevertheless, this fall offers an opportunity to investors given the company's strong future prospects, say analysts.To begin with, Natco's revenues fell 16 per cent year-on-year to Rs 5.6 billion in Q3, mainly due to the high base of last year which had seen large contribution from another mega product Tamiflu generic (anti-viral drug for flu treatment) launched on exclusivity basis. Analysts also attribute the miss in revenues to subdued performance of Hepatitis-C business in India and partly due to lower-than-expected revenue ...